Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-303 in advanced solid tumors
NCT06158958Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Trispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of DF4101 in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more (7 arms), sponsored by AbbVie Inc. Primary endpoint: Adverse Events at 3 years. Started Feb 2024; status: terminated.
02
Drugs
DF4101
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06158958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158958.